Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114 EUR | +0.13% |
|
-.--% | -.--% |
06-26 | DSM-Firmenich Unit Issues EUR800 Million Bond | MT |
06-26 | DSM-Firmenich Issues ?800 Million Long-Term Bond | CI |
Sales 2024 * | 12.6B 13.5B 18.47B | Sales 2025 * | 13.27B 14.22B 19.45B | Capitalization | 28.01B 30.01B 41.05B |
---|---|---|---|---|---|
Net income 2024 * | 459M 492M 673M | Net income 2025 * | 795M 852M 1.16B | EV / Sales 2024 * | 2.45 x |
Net Debt 2024 * | 2.84B 3.04B 4.16B | Net Debt 2025 * | 2.57B 2.75B 3.76B | EV / Sales 2025 * | 2.3 x |
P/E ratio 2024 * |
61
x | P/E ratio 2025 * |
35.2
x | Employees | 28,685 |
Yield 2024 * |
2.38% | Yield 2025 * |
2.34% | Free-Float | 25.03% |
Latest transcript on Koninklijke DSM
1 day | +0.13% |
![Extreme 105.8](/images/extremecours_fleche.png)
![Extreme 82.2](/images/extremecours_fleche.png)
![Extreme 38.71](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 57 | 89-12-31 | |
Ralf Schmeitz
DFI | Director of Finance/CFO | - | 23-08-31 |
Sarah Reisinger
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-01-31 | |
Thomas Leysen
CHM | Chairman | 63 | 23-01-31 |
Director/Board Member | 62 | 23-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.43% | 342 M€ | +17.69% | ||
1.13% | 21 M€ | +9.81% | - |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.83% | 881B | |
+2.13% | 243B | |
+24.56% | 176B | |
+1.83% | 140B | |
-9.54% | 70.84B | |
-6.52% | 57.09B | |
+109.08% | 35.76B | |
-37.23% | 32.94B | |
+28.44% | 32.6B |
- Stock Market
- Equities
- DSFIR Stock
- DSM Stock